GPT and metabolic dysfunction-associated steatotic liver disease: This result aligns with the conclusion that PF-05231023 treatment reduces liver TC and TG in NAFLD, and reduces plasma liver injury markers alanine aminotransferase and aspartate aminotransferase (10).